Book an appointment with Boardroom Media using SetMore
Connect with us

AdAlta Signs Manufacturing Agreement

MELBOURNE Australia, 5 June, 2018: AdAlta Limited (ASX:1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to
invite investors to listen to an audio interview with CEO and Managing Director, Sam Cobb, where she discusses AdAlta’s recent manufacturing update to progress the company’s improved lung fibrosis therapy, AD-214 to the clinic.

Listen here: 

CEO of AdAlta, Sam Cobb speaks on the AD-214 manufacturing agreement